The European Prevention of
Alzheimer’s Dementia
Consortium

There’s an urgent need to break new ground in the fight against Alzheimer’s dementia. The number of people affected worldwide is expected to reach over 100 million by 2050. Therefore, right now is a crucial time for the development of effective treatments.

We recruited over 2000 research participants into a four-year EPAD Longitudinal Cohort Study (LCS) exploring new ways to better understand the early stages of Alzheimer’s disease and prevent dementia before symptom onset.

The data, bio samples, and neuroimaging generated from our study are available for researchers studying the brain and neurodegenerative diseases around the world.

EPAD at AD/PD 2024: Advances in Science and Therapy

International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders | March 5-9, 2024 | Lisbon, Portugal |

Learn more

>

Explore our Open Source Data and Samples

By making our data and samples publicly accessible, our goal is to facilitate global collaboration amongst brain scientists and researchers working in the field to improve the understanding of the early stages of Alzheimer’s disease and accelerate treatment options.

Thanks to an innovative screening process, the EPAD LCS dataset is unique, as 37% of the sample was amyloid positive at enrollment. Additional data includes information on biomarkers, cognition, sociodemographic, and vital signs.

The EPAD imaging dataset includes core (3D T1w, 3D FLAIR) and advanced (ASL, diffusion MRI, and resting-state fMRI) MRI sequences. Core Sequences were acquired for all participants while advanced sequences have been obtained from a subset of scanning sites, for around 70% of
participants.

The EPAD biobank includes blood, CSF, saliva, and urine collected over the course of our longitudinal study. Our bespoke database and information management system provides traceability and sample
validation.

Discover the latest EPAD news and publications.

  • Annals of Clinical and Translational Neurology

    “Alzheimer’s Disease and Small Vessel Disease Differentially Affect White Matter Microstructure” Authors: Mario Tranfa, Luigi Lorenzini, Lyduine E. Collij, David Vállez García, Silvia Ingala, Giuseppe Pontillo, Leonard Pieperhoff, Alessio Maranzano, Robin Wolz, Sven Haller, Kaj Blennow, Giovanni Frisoni, Carole H. Sudre, Gael Chételat, Michael Ewers, Pierre Payoux, Adam Waldman, Pablo Martinez-Lage, Adam J. Schwarz, Craig W. Ritchie, Joanna M. Wardlaw, Juan Domingo Gispert, Arturo Brunetti, Henk J. M. M. Mutsaerts, Alle Meije Wink, Frederik Barkhof Abstract: Objective: Alzheimer’s disease (AD)…

    Read more: Annals of Clinical and Translational Neurology

If you’re looking to collaborate, we’re here to help.